UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

Value in health, 2004-09, Vol.7 (5), p.518-528

2004

Volltextzugriff (PDF)

Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever

American journal of health-system pharmacy, 2007-03, Vol.64 (6), p.637-643

2007

Volltextzugriff (PDF)

Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries

Clinical infectious diseases, 2006-08, Vol.43 (4), p.e29-e38

2006

Volltextzugriff (PDF)

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada

Allergy, asthma, and clinical immunology, 2014-05, Vol.10 (1), p.23-23, Article 23

2014

Volltextzugriff (PDF)

Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes

Clinical therapeutics, 2001-12, Vol.23 (12), p.1999-2010

2001

Volltextzugriff (PDF)

Antihypertensive persistence and drug class

Canadian journal of cardiology, 2002-06, Vol.18 (6), p.649-656

2002

Volltextzugriff (PDF)

Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation

Diabetes care, 2003-03, Vol.26 (3), p.683-687

2003

Volltextzugriff (PDF)

Compliance and persistence with newer antihypertensive agents

Current hypertension reports, 2002-12, Vol.4 (6), p.424-433

Gerth, William C

2002

Volltextzugriff (PDF)

Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions

Pharmacoepidemiology and drug safety, 2005-11, Vol.14 (11), p.755-767

2005

Volltextzugriff (PDF)

Burden of hospitalization of patients with Candida and Aspergillus infections in Australia

International journal of infectious diseases, 2004-03, Vol.8 (2), p.111-120

2004

Volltextzugriff (PDF)

Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis

Clinical therapeutics, 2005-06, Vol.27 (6), p.960-969

2005

Volltextzugriff (PDF)

Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union

Kidney international, 2002-12, Vol.62 (S82), p.S68-S72

2002

Volltextzugriff (PDF)

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy

PharmacoEconomics, 2006-01, Vol.24 (6), p.549-558

2006

Volltextzugriff (PDF)

Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model

Journal of occupational and environmental medicine, 2004-01, Vol.46 (1), p.48-54

2004

Volltextzugriff (PDF)

Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan

Journal of antimicrobial chemotherapy, 2006-06, Vol.57 (6), p.1181-1188

2006

Volltextzugriff (PDF)

Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective

Canadian journal of cardiology, 2004-05, Vol.20 (6), p.613-618

2004

Volltextzugriff (PDF)

OR-65: Losartan/angiotensin II antagonists have greater persistence than other antihypertensive agents/classes

American journal of hypertension, 2002-04, Vol.15 (S3), p.29A-29A

2002

Volltextzugriff (PDF)

Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease

Diabetes care, 2003-03, Vol.26 (3), p.683-687

2003

Volltextzugriff (PDF)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada

Allergy, asthma, and clinical immunology, 2014-03, Vol.10 (S1), p.A42-A42, Article A42

2014

Volltextzugriff (PDF)

O-23: Angiotensin II antagonists demonstrate greater long-term persistence versus other antihypertensive medications

American journal of hypertension, 2001-04, Vol.14 (S1), p.10A-10A

2001

Volltextzugriff (PDF)

The multinational impact of migraine symptoms on healthcare utilisation and work loss

PharmacoEconomics, 2001, Vol.19 (2), p.197-206

2001

Volltextzugriff (PDF)

The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure

Cardiology, 1999-01, Vol.91 (3), p.189-194

1999

Volltextzugriff (PDF)

Use of a structured migraine diary improves patient and physician communication about migraine disability and treatment outcomes

International journal of clinical practice (Esher), 2005-03, Vol.59 (3), p.281-286

2005

Volltextzugriff (PDF)

PATIENT‐REPORTED BENEFITS OF RIZATRIPTAN COMPARED WITH USUAL NON‐TRIPTAN THERAPY FOR MIGRAINE IN A PRIMARY CARE SETTING

International journal of clinical practice (Esher), 2003-11, Vol.57 (9), p.761-768

2003

Volltextzugriff (PDF)

Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial

Canadian journal of clinical pharmacology, 2002, Vol.9 (3), p.158

2002

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(37)
Bücher
(1)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever

Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada

Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes

Antihypertensive persistence and drug class

Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation

Compliance and persistence with newer antihypertensive agents

Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions

Burden of hospitalization of patients with Candida and Aspergillus infections in Australia

Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis

Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy

Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model

Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan

Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective

OR-65: Losartan/angiotensin II antagonists have greater persistence than other antihypertensive agents/classes

Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada

O-23: Angiotensin II antagonists demonstrate greater long-term persistence versus other antihypertensive medications

The multinational impact of migraine symptoms on healthcare utilisation and work loss

The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure

Use of a structured migraine diary improves patient and physician communication about migraine disability and treatment outcomes

PATIENT‐REPORTED BENEFITS OF RIZATRIPTAN COMPARED WITH USUAL NON‐TRIPTAN THERAPY FOR MIGRAINE IN A PRIMARY CARE SETTING

Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial

Suchergebnisse filtern